65,437 trials
Colorectal Surgery
Primary: The Primary Objective Measures the Proportion of Patients With Superficial Site Infection as Defined by the CDC. — 40; 46 Participants
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48, as a Function of APOE ε4 Status in APOE4 Negatives…
Chronic Hepatitis C · Hepatitis C (HCV) · Hepatitis C Genotype 1a
Primary: Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12 — -0.464; -0.148; -0.611…
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Objective Tumor Response According to RECIST — 2 Participants
Interstitial Cystitis · Bladder Pain Syndrome
Primary: Change From Baseline in the Average Daily Bladder Pain Score (e-Diary) — 6.4; 6.7; -2.4; -1.4 units on a scale — p=0.061
Thoracic Aortic Aneurysms · and Penetrating Atherosclerotic Ulcers
Primary: Primary Effectiveness Endpoint: Freedom From Major Adverse Device Effects — 97 participants — p=>0.80
Severe, Refractory Asthma · Airway Inflammation · Airflow Obstruction
Primary: 16 Weeks - Juniper Asthma Quality of Life Questionnaire (AQLQ) Score — 4.7; 4.6 units on a scale
Uterine Cervical Neoplasms · Endometrial Neoplasms · Anus Neoplasms
Primary: Percent Difference From Baseline IMRT Plan (%) — -4.7; -9.3; -14.2; -13.4 Percent difference (%)
Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) — 25; 18 participants — p=0.34
Bronchiectasis
Primary: Time to First Exacerbation Event Within 48 Weeks - Cipro 28 vs. Pooled Placebo — NA; NA Days — p=0.0511
Heart Failure
Primary: Primary Safety Endpoint is to Evaluate the System-related Complication-free Rate — 84.2 Percentage of participants
Influenza
Primary: Time to Alleviation of Influenza Symptoms — 102.30; 103.20; 104.10 hours — p=0.251
Recurrent Osteosarcoma
Primary: Disease Control Success — 0 participants
Dermal Irritation
Primary: Number of Subjects That Showed Erythema Based on 5 Point Scoring Scale — 0 Participants
Type-2 Diabetes Mellitus · Coronary Artery Disease
Primary: Thrombus Formation — 66.9; 84.4; 59.9; 79.8 percentage of baseline size